Literature DB >> 3102678

Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells.

A N Houghton, F X Real, L J Davis, C Cordon-Cardo, L J Old.   

Abstract

Phenotypic heterogeneity is a characteristic feature of tumor lesions in patients with melanoma. Variability can be observed in cell morphology, pigmentation, and antigen expression. To test whether phenotypic heterogeneity could be the result of events regulated during cell differentiation, we evaluated the expression of a panel of differentiation traits on melanoma cells. Metastatic melanoma lesions from two patients, designated FD and AP, were examined histologically and found to contain mixed populations of cells. Established melanoma cell lines derived from each of these lesions were subcloned at early passage in culture (passages 7 and 8) to create a panel of clones derived from each tumor. There was heterogeneity in the expression of differentiation-related traits in clones, corresponding to distinct phenotypes observed within the original tumors. Clones from patient FD corresponded to early to intermediate stages of melanocyte differentiation, and clones from patient AP ranged from intermediate to late stages. The influence of cholera toxin and PMA on differentiation of parental cultures and subclone was studied. Results of induction studies demonstrated a number of features of differentiation of melanoma cells: regulation of differentiation traits is coordinated as a program of traits expressed sequentially at specific stages; early traits, such as the epidermal growth factor receptor and the melanoma chondroitin sulfate proteoglycan antigen, are downregulated as melanoma cells differentiate, whereas late markers, including melanin, tyrosinase activity, and antigens expressed in mature melanosomes, are upregulated; Ia (class II major histocompatibility) antigens are characteristically expressed on melanomas corresponding to early or intermediate stages of differentiation and are regulated as part of the differentiation program; minimal changes in stage of differentiation were observed during induction of parental cultures with either cholera toxin or PMA, whereas definite shifts in differentiation could be induced in selected cloned subpopulations. We conclude that melanoma cells are not frozen at a specific stage of differentiation, but rather are capable of differentiating when exposed to appropriate signals. Diversity in the differentiation state of melanoma cells can account for much of the phenotypic heterogeneity observed in melanoma lesions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102678      PMCID: PMC2188299          DOI: 10.1084/jem.165.3.812

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  38 in total

1.  Control of phenotypic expression of cultured melanoma cells by melanocyte stimulating hormones.

Authors:  G Wong; J Pawelek
Journal:  Nat New Biol       Date:  1973-02-14

2.  N 6 ,O 2 '-dibutyryl adenosine 3',5'-monophosphate induces pigment production in melanoma cells.

Authors:  G S Johnson; I Pastan
Journal:  Nat New Biol       Date:  1972-06-28

Review 3.  The migration and differentiation of neural crest cells.

Authors:  J A Weston
Journal:  Adv Morphog       Date:  1970

4.  Melanocyte-stimulating hormone promotes activation of pre-existing tyrosinase molecules in Cloudman S91 melanoma cells.

Authors:  G Wong; J Pawelek
Journal:  Nature       Date:  1975-06-19       Impact factor: 49.962

5.  Tyrosinase maturation and pigment expression in B16 melanoma: relation to theophylline treatment and intracellular cyclic AMP.

Authors:  R White; G C Hanson
Journal:  J Cell Physiol       Date:  1979-06       Impact factor: 6.384

6.  Expression of Ia-like antigens on cultured human malignant melanoma cell lines.

Authors:  R J Winchester; C Y Wang; A Gibofsky; H G Kunkel; K O Lloyd; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

7.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

8.  Effect of phorbol ester tumor promoters on the expression of melanogenesis in B-16 melanoma cells.

Authors:  R A Mufson; P B Fisher; I B Weinstein
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

9.  Cholera toxin mimics melanocyte stimulating hormone in inducing differentiation in melanoma cells.

Authors:  E O'Keefe; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1974-06       Impact factor: 11.205

10.  L-tyrosine-3,5-3H assay for tyrosinase development in skin of newborn hamsters.

Authors:  S H Pomerantz
Journal:  Science       Date:  1969-05-16       Impact factor: 47.728

View more
  42 in total

1.  Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells.

Authors:  T Palomares; A Alonso-Varona; A Alvarez; B Castro; Y Calle; P Bilbao
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

2.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

3.  DNA content and MHC class II antigen expression in malignant melanoma: clinical course.

Authors:  J Zaloudik; M Moore; A K Ghosh; Z Mechl; A Rejthar
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

4.  Selective increase in specific alternative splice variants of tyrosinase in murine melanomas: a projected basis for immunotherapy.

Authors:  N Le Fur; S R Kelsall; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Changes in expression of putative antigens encoded by pigment genes in mouse melanomas at different stages of malignant progression.

Authors:  S J Orlow; V J Hearing; C Sakai; K Urabe; B K Zhou; W K Silvers; B Mintz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  Human melanoma-associated antigen expression on human neuroblastoma cells: effects of differentiation inducers.

Authors:  V Feyles; W T Dixon; L K Sikora; R C McGarry; L M Jerry
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Locally increased metastatic efficiency as a reason for preferential metastasis of solid tumors to lymph nodes.

Authors:  G F Whalen; S F Sharif
Journal:  Ann Surg       Date:  1992-02       Impact factor: 12.969

8.  Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.

Authors:  M Maio; B Gulwani; S Tombesi; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.

Authors:  P Nisticò; R Mortarini; L B De Monte; A Mazzocchi; M Mariani; F Malavasi; G Parmiani; P G Natali; A Anichini
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Tyrosine transport in a human melanoma cell line as a basis for selective transport of cytotoxic analogues.

Authors:  J M Pankovich; K Jimbow
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.